Recombinant MBL

Recombinant Mannose Binding Lectin

Immunotherapeutic protein to suppress the infection of the broad range of pathogenic micro-organisms as the first line of defense

R&D Goals

MBL in human blood recognizes carbohydrate patterns, found on the surface of a large number of pathogenic micro-organisms, including bacteria, viruses, protozoa and fungi. Binding of MBL to a micro-organism results in activation of the lectin pathway of the complement system mediated by complexes of MBL with a serine protease called MBL-associated serine protease 2 (MASP-2). MASP protein functions to cleave the blood protein C4 into C4a and C4b. The C4b fragments can then bind to the surface of the bacterium, and initiate the formation of a C3-convertase.

The subsequent complement cascade catalyzed by C3-convertase results in creating a membrane attack complex, which causes lysis of the pathogen as well as altered-self in the context of apoptotic and necrotic cells.

MBL plays an important role in the first line of defense against a wide range of pathogens and in inducing the adaptive immune response.

We have developed recombinant MBL which forms oligomer complex and shows fully functional. Recombinant MBL can be developed as immuno-therapeutics for various infectious diseases.

Features of Recombinant MBL
  • Flower bouquet-like fully functional MBL is produced as recombinant protein in commercial scale

  • Formulated MBL to deliver any quantity to the site of infection of microbes (Airway surface and lung).

  • Recombinant MBL can be developed as antiviral, antibacterial and antifungal agents